Colorectal Liver Metastasis

Dr. Jean-Nicolas Vauthey is Chief of the Hepato-Pancreato-Biliary Section in the Department of Surgical Oncology at The University of Texas MD Anderson Cancer Center and the Dallas Fort Worth Living Legend in Clinical Cancer Research Chair in Houston, USA. Dr. Vauthey co-authored more than 600 publications in peer-reviewed journals (h-index, 107) and more than 100 reviews and book chapters in major textbooks. Dr. Vauthey's clinical research focuses on methods to measure and to improve outcome after hepatic resection for hepatobiliary malignancies. Dr. Vauthey proposed a standardized method for calculating the volume of the anticipated liver remnant prior to liver surgery. Dr. Vauthey has evaluated the use of preoperative chemotherapy in the multidisciplinary treatment of patients with hepatic colorectal metastases. He has pioneered the use of 2-stage hepatectomy for patients with advanced metastatic colorectal carcinoma to liver. Dr. Vauthey's most recent work has focused on somatic mutations, circulating tumor DNA and their role in defining response, treatment, surveillance and prognosis after resection of colorectal liver metastases.Dr. Yoshikuni Kawaguchi is Deputy Chief (Inpatient Care) of Hepato-Biliary-Pancreatic Surgery Division in the Department of Surgery at The University of Tokyo. Dr. Kawaguchi co-authored more than 130 publications in peer-reviewed journals (h-index, 25). Dr. Kawaguchi's interest in clinical research is to improve short- and long-term outcomes of patients undergoing surgery for hepato-biliary-pancreatic diseases. Dr. Kawaguchi proposed a novel 3-level classification system for open and minimally-invasive liver resection, which is associated with liver resection complexity and postoperative complications. Dr. Kawaguchi has recently worked with Dr. Vauthey to improve the understanding of multiple somatic mutations of colorectal liver metastases for clinical practices including accurate prognostication after resection and recurrence risk-adjusted surveillance algorithm. Professor Rene Adam is president of the Medical Board of the Paul Brousse Hospital, Villejuif, France and head of the Oncological Surgery Unit of the Hepato Biliary Center. Since 1994, he has held the position of professor of surgery at the Faculty of Medicine Kremlin Bicetre at Paris South University, Paris. Professor Adam's main fields of activity and research are surgery of the liver, biliary tract and pancreas, and hepatic transplantation. He is particularly involved in the treatment of hepatocellular carcinoma and of liver metastases.

1 History of treatment of colorectal liver metastases 2 Anatomy 3 Exposure 4 Anatomic versus non-anatomic resection 5 Simulation and navigation 6 Advanced techniques in multiple metastases: fiduciary markers and completion ablation 7 Two-stage hepatectomy for biloblar colorectal liver metastases: experience of MD Anderson Cancer Center 8 Two-stage hepatectomy for biloblar colorectal liver metastases: experience of Hôpital Paul-Brousse 9 One-stage hepatectomy for biloblar colorectal liver metastases: experience of the University of Tokyo 10 Associated Liver Partition and Portal vein ligation for Staged hepatectomy (ALLPS) 11 Open resection technique 12 Laparoscopic resection technique: Norwegian experience 13 Laparoscopic resection technique: French experience 14 Laparoscopic resection technique: Japanese experience 15 Is there a place for robotic resection? 16 Advanced resection technique with vascular reconstruction 17 Resection margins 18 R1 vascular resection 19 Prevention and treatment of perihepatic fluid collection including two-step air leak test 20 Synchronous presentation of primary and colorectal liver metastasis: classic, reverse, and combined 21 Approach to synchronous lung and liver metastases and single incision combined resection 22 Perioperative chemotherapy: review of randomized trials and recommended approach 23 The disappearing metastasis 24 Downsizing of unresectable colorectal liver metastasis 25 Is there a place for debulking? 26 Liver transplantation 27 Prognostic model for colorectal liver metastasis 28 Personalized prognostic model (contour model) 29 Conditional recurrence-free survival 30 Repeat Hepatectomy: Rationale and Results 31 Initial systemic chemotherapy for metastatic CRC 32 Treatment refractory metastatic CRC 33 Targeted therapy beyond EGFR and VEGF 34 Adjuvant systemic chemotherapy 35 Immunotherapy 36 Infusional therapy: European experience 37 Infusional therapy: American experience 38 Optimal diagnostic imaging of CLM in surgical candidates 39 Prevention of postoperative liver insufficiency including standardized future liver remnant and kinetic growth rate 40 Portal vein embolization with and without hepatic vein occlusion 41 Radiofrequency ablation, electroporation and microwave ablation 42 Radiation therapy 43 Radioembolization 44 Hepatic injury from chemotherapy 45 Imaging response criteria 46 Pathological response criteria 47 Histopathological patterns of progression and vessel co-option 48 Micrometastasis 49 Liquid biopsy 50 Multigene testing for prognostication and therapeutic actionability 51 Cancer-related signaling pathway and prognosis 52 Intra-operative ultrasound 53 Hybrid room for combined procedures 54 Liver tumor board 55 Role of advanced practice providers in enhancing perioperative and intraoperative patient care 56 Enhanced recovery after liver resection 57 Improved survival after CLM resection over 20 years 58 LiverMetSurvey registry 59 Surveillance strategy and circulating DNA